Literature DB >> 22887810

BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.

N Paul Ohori1, Rashi Singhal, Marina N Nikiforova, Linwah Yip, Karen E Schoedel, Christopher Coyne, Kelly L McCoy, Shane O LeBeau, Steven P Hodak, Sally E Carty, Yuri E Nikiforov.   

Abstract

BACKGROUND: BRAF mutations are highly specific for papillary thyroid carcinoma (PTC) and many cytology specimens with BRAF mutations are expected to demonstrate cytologic features typical of PTC. However, indeterminate thyroid cytology cases are inevitable and understanding the significance of the BRAF mutation within the context of the Bethesda System for Reporting Thyroid Cytopathology would be valuable.
METHODS: Thyroid cytology cases submitted for conventional cytomorphologic evaluation and BRAF mutational analyses were selected from the authors' cytopathology files from April 2007 to October 2011. From this group, the diagnostic usefulness of BRAF mutations in indeterminate and malignant cases was assessed and analyses of cytologic and histopathologic features associated with the mutations in this gene were performed.
RESULTS: A total of 131 cases with a BRAF mutation were identified. Of these, 119 underwent surgical pathology resection follow-up and demonstrated PTC. Approximately 75% of the cases were cytologically diagnosed as being positive for malignancy and these cases were associated with both the classic and tall cell variants of PTC at the time of resection, a greater likelihood of extrathyroidal extension, and the V600E type of BRAF mutation. In contrast, BRAF-mutated cases with diagnoses of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) and follicular neoplasm/suspicious for follicular neoplasm were found to be more strongly associated with the follicular variant of PTC, a K601E BRAF mutation, and a lower likelihood of extrathyroidal extension. However, a subset of AUS/FLUS cases with the V600E BRAF mutation appeared to represent sampling variability of the classic or tall cell variants of PTC.
CONCLUSIONS: Bethesda thyroid diagnoses in the setting of a BRAF mutation reflect differences in PTC subtypes, the nature of cytology specimens, and molecular characteristics.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22887810     DOI: 10.1002/cncy.21229

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  23 in total

Review 1.  Cytopathologic diagnosis of fine needle aspiration biopsies of thyroid nodules.

Authors:  Evangelos P Misiakos; Niki Margari; Christos Meristoudis; Nickolas Machairas; Dimitrios Schizas; Konstantinos Petropoulos; Aris Spathis; Petros Karakitsos; Anastasios Machairas
Journal:  World J Clin Cases       Date:  2016-02-16       Impact factor: 1.337

Review 2.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

3.  Preoperative diagnosis of benign thyroid nodules with intermediate cytology.

Authors:  Muhammad Ghanem; Yair Levy; Haggi Mazeh
Journal:  Gland Surg       Date:  2012-08

4.  Atypia of Undetermined Significance in Thyroid Fine Needle Aspirates: a 4-Year Audit of Thy3a Reporting.

Authors:  Dorinda Mullen; Sarah Mullins; Aoife Doyle; Rachel K Crowley; Stephen Skehan; Enda W McDermott; Ruth S Prichard; David Gibbons
Journal:  Eur Thyroid J       Date:  2017-07-17

Review 5.  Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules.

Authors:  Linwah Yip; Robert L Ferris
Journal:  Otolaryngol Clin North Am       Date:  2014-06-12       Impact factor: 3.346

6.  Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules.

Authors:  Lingying Yu; Lizhen Ma; Qiaofeng Tu; Y I Zhang; Yueming Chen; Daojun Yu; Shaoyu Yang
Journal:  Oncol Lett       Date:  2015-04-15       Impact factor: 2.967

Review 7.  The Role and Importance of Molecular Tests in Approach to Thyroid Nodules.

Authors:  Levent Gürbüzler
Journal:  Turk Arch Otorhinolaryngol       Date:  2016-04-06

8.  Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.

Authors:  Linwah Yip; Marina N Nikiforova; Jenny Y Yoo; Kelly L McCoy; Michael T Stang; Michaele J Armstrong; Kristina J Nicholson; N Paul Ohori; Christopher Coyne; Steven P Hodak; Robert L Ferris; Shane O LeBeau; Yuri E Nikiforov; Sally E Carty
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

9.  BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.

Authors:  Anna Guerra; Vincenza Di Stasi; Pio Zeppa; Antongiulio Faggiano; Vincenzo Marotta; Mario Vitale
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

10.  Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.

Authors:  Jieun Koh; Jong Rak Choi; Kyung Hwa Han; Eun-Kyung Kim; Jung Hyun Yoon; Hee Jung Moon; Jin Young Kwak
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.